Thermo Fisher Scientific Inc. 03.31.16
Waltham, Mass.-based Thermo Fisher Scientific Inc. has completed the acquisition of Santa Clara, Calif.-based Affymetrix Inc. in a deal valued at approximately $1.3 billion. Completion of the transaction follows approval of the merger agreement by Affymetrix stockholders at the special meeting held on March 31.
“We are pleased to announce the completion of this transaction and officially welcome the Affymetrix team to Thermo Fisher,” said Marc N. Casper, president and CEO of Thermo Fisher Scientific. “This is a great outcome for both companies. With Affymetrix, we now have an expanded antibody portfolio to strengthen our leadership in biosciences, as well as new genetic analysis capabilities to better serve clinical and applied markets. Our combined capabilities will benefit our customers, employees and shareholders, and we are excited to move forward as one organization positioned for growth. Since first announcing our agreement back in January, the integration planning has been progressing well and we look forward to creating value through the strategic and financial benefits of the transaction.”
“This transaction creates significant value for our stockholders and will provide important benefits to our customers and employees,” said Frank Witney, president and CEO of Affymetrix. “I want to thank all of our stakeholders, including our dedicated employees, for their contributions to the company’s success and their support throughout this process. We believe Affymetrix will be positioned for long-term success as part of Thermo Fisher.”
As a result of the completion of the transaction, Affymetrix stock will cease trading and will no longer be listed on The NASDAQ Global Select Market.
JP Morgan acted as financial advisor to Thermo Fisher, and Wachtell, Lipton, Rosen & Katz served as legal counsel. Morgan Stanley acted as financial advisor to Affymetrix, and Davis Polk & Wardwell LLP served as legal counsel.
Afymetrix makes technologies to enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level, and to facilitate the rapid translation of benchtop research into clinical and routine use for human health and wellness.
Through its various brands, Thermo Fisher Scientific helps its customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity.
“We are pleased to announce the completion of this transaction and officially welcome the Affymetrix team to Thermo Fisher,” said Marc N. Casper, president and CEO of Thermo Fisher Scientific. “This is a great outcome for both companies. With Affymetrix, we now have an expanded antibody portfolio to strengthen our leadership in biosciences, as well as new genetic analysis capabilities to better serve clinical and applied markets. Our combined capabilities will benefit our customers, employees and shareholders, and we are excited to move forward as one organization positioned for growth. Since first announcing our agreement back in January, the integration planning has been progressing well and we look forward to creating value through the strategic and financial benefits of the transaction.”
“This transaction creates significant value for our stockholders and will provide important benefits to our customers and employees,” said Frank Witney, president and CEO of Affymetrix. “I want to thank all of our stakeholders, including our dedicated employees, for their contributions to the company’s success and their support throughout this process. We believe Affymetrix will be positioned for long-term success as part of Thermo Fisher.”
As a result of the completion of the transaction, Affymetrix stock will cease trading and will no longer be listed on The NASDAQ Global Select Market.
JP Morgan acted as financial advisor to Thermo Fisher, and Wachtell, Lipton, Rosen & Katz served as legal counsel. Morgan Stanley acted as financial advisor to Affymetrix, and Davis Polk & Wardwell LLP served as legal counsel.
Afymetrix makes technologies to enable multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level, and to facilitate the rapid translation of benchtop research into clinical and routine use for human health and wellness.
Through its various brands, Thermo Fisher Scientific helps its customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity.